FI114341B - Avidiinin tai streptavidiinin käyttö häiriönpoistoaineena immunologisissa määrityksissä ja määritysmenetelmät, joissa käytetään tätä ainetta - Google Patents
Avidiinin tai streptavidiinin käyttö häiriönpoistoaineena immunologisissa määrityksissä ja määritysmenetelmät, joissa käytetään tätä ainetta Download PDFInfo
- Publication number
- FI114341B FI114341B FI963461A FI963461A FI114341B FI 114341 B FI114341 B FI 114341B FI 963461 A FI963461 A FI 963461A FI 963461 A FI963461 A FI 963461A FI 114341 B FI114341 B FI 114341B
- Authority
- FI
- Finland
- Prior art keywords
- avidin
- streptavidin
- eller
- biotin
- derivative
- Prior art date
Links
- 108010090804 Streptavidin Proteins 0.000 title claims description 139
- 108090001008 Avidin Proteins 0.000 title claims description 107
- 238000000034 method Methods 0.000 title claims description 33
- 238000003556 assay Methods 0.000 title claims description 30
- 239000003795 chemical substances by application Substances 0.000 title claims description 25
- 238000003018 immunoassay Methods 0.000 title claims description 23
- 230000001430 anti-depressive effect Effects 0.000 title 1
- 239000000935 antidepressant agent Substances 0.000 title 1
- 229940005513 antidepressants Drugs 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 113
- 229960002685 biotin Drugs 0.000 claims description 64
- 239000011616 biotin Substances 0.000 claims description 64
- 235000020958 biotin Nutrition 0.000 claims description 57
- 238000009739 binding Methods 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 47
- 239000012491 analyte Substances 0.000 claims description 38
- 230000009870 specific binding Effects 0.000 claims description 24
- 230000002452 interceptive effect Effects 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 150000001615 biotins Chemical class 0.000 claims description 15
- 239000007790 solid phase Substances 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 230000003993 interaction Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000007826 nucleic acid assay Methods 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 238000005470 impregnation Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 238000000137 annealing Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000011331 genomic analysis Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000872 buffer Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 239000003463 adsorbent Substances 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000036436 anti-hiv Effects 0.000 description 7
- 229910000160 potassium phosphate Inorganic materials 0.000 description 7
- 239000008057 potassium phosphate buffer Substances 0.000 description 7
- 235000011009 potassium phosphates Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- -1 2-pyridylthio Chemical group 0.000 description 5
- 241001362551 Samba Species 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- ZRTJVRDXVSDKPX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-acetylsulfanylpropanoate Chemical compound CC(=O)SCCC(=O)ON1C(=O)CCC1=O ZRTJVRDXVSDKPX-UHFFFAOYSA-N 0.000 description 1
- RBAFCMJBDZWZIV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azido-2-hydroxybenzoate Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O RBAFCMJBDZWZIV-UHFFFAOYSA-N 0.000 description 1
- LWAVGNJLLQSNNN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O LWAVGNJLLQSNNN-UHFFFAOYSA-N 0.000 description 1
- NGXDNMNOQDVTRL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(4-azido-2-nitroanilino)hexanoate Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCCCCC(=O)ON1C(=O)CCC1=O NGXDNMNOQDVTRL-UHFFFAOYSA-N 0.000 description 1
- HEXATKOCYDZCRX-WJBIIUEVSA-N (3as,4s,6ar)-4-[6-amino-7-[2-(2-aminoethoxy)ethoxy]-5-oxoheptyl]-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)C(N)COCCOCCN)SC[C@@H]21 HEXATKOCYDZCRX-WJBIIUEVSA-N 0.000 description 1
- XKQYCEFPFNDDSJ-UHFFFAOYSA-N 1-[3-[2-[(4-azido-2-hydroxybenzoyl)amino]ethyldisulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)NCCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O XKQYCEFPFNDDSJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- PQXPAFTXDVNANI-UHFFFAOYSA-N 4-azidobenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1 PQXPAFTXDVNANI-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- HRLAPUHJWRZEIC-UHFFFAOYSA-N 4-nitrobenzenesulfonyl fluoride Chemical compound [O-][N+](=O)C1=CC=C(S(F)(=O)=O)C=C1 HRLAPUHJWRZEIC-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZSBDPRIWBYHIAF-UHFFFAOYSA-N N-acetyl-acetamide Natural products CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 1
- PXBIVKDMIUOEKV-UHFFFAOYSA-N N=C1CCCS1.ClC1=NC(Cl)=NC(Cl)=N1 Chemical compound N=C1CCCS1.ClC1=NC(Cl)=NC(Cl)=N1 PXBIVKDMIUOEKV-UHFFFAOYSA-N 0.000 description 1
- LECVSUDKRHNAST-CAGKOAJJSA-N NCCOCCOCCNC(C(C=C1)=CC=C1N=[N+]=[N-])=O.OC(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)=O Chemical compound NCCOCCOCCNC(C(C=C1)=CC=C1N=[N+]=[N-])=O.OC(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)=O LECVSUDKRHNAST-CAGKOAJJSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108700031620 S-acetylthiorphan Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108091005646 acetylated proteins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LWISPDYGRSGXME-YDHLFZDLSA-N biotin peg2 amine Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCN)SC[C@@H]21 LWISPDYGRSGXME-YDHLFZDLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- AJJLGMCBXZSSSA-UHFFFAOYSA-N ethyl 4-(4-azidophenyl)sulfanylbutanimidothioate;hydrochloride Chemical compound Cl.CCSC(=N)CCCSC1=CC=C(N=[N+]=[N-])C=C1 AJJLGMCBXZSSSA-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JZLFUUHOTZKEFU-UHFFFAOYSA-N methyl 4-azidobenzenecarboximidate Chemical compound COC(=N)C1=CC=C(N=[N+]=[N-])C=C1 JZLFUUHOTZKEFU-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000000101 transmission high energy electron diffraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4407423A DE4407423A1 (de) | 1994-03-05 | 1994-03-05 | Entstörmittel zum Einsatz bei Immunoassays |
| DE4407423 | 1994-03-05 | ||
| PCT/EP1995/000690 WO1995023800A1 (fr) | 1994-03-05 | 1995-02-25 | Derives photoactivables de la biotine et leur utilisation pour la suppression des interactions dans les dosages immunologiques |
| EP9500690 | 1995-02-25 | ||
| EP9500776 | 1995-03-03 | ||
| PCT/EP1995/000776 WO1995023801A1 (fr) | 1994-03-05 | 1995-03-03 | Produit de suppression des interactions dans les dosages immunologiques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI963461A0 FI963461A0 (fi) | 1996-09-04 |
| FI963461A FI963461A (fi) | 1996-09-04 |
| FI114341B true FI114341B (fi) | 2004-09-30 |
Family
ID=25934426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI963461A FI114341B (fi) | 1994-03-05 | 1996-09-04 | Avidiinin tai streptavidiinin käyttö häiriönpoistoaineena immunologisissa määrityksissä ja määritysmenetelmät, joissa käytetään tätä ainetta |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5863740A (fr) |
| JP (1) | JP3027770B2 (fr) |
| CA (1) | CA2184386C (fr) |
| FI (1) | FI114341B (fr) |
| WO (1) | WO1995023801A1 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4434093A1 (de) * | 1994-09-23 | 1996-03-28 | Boehringer Mannheim Gmbh | Verfahren zum qualitativen oder/und quantitativen Nachweis einer zu bestimmenden Substanz |
| IL114149A0 (en) * | 1995-06-14 | 1995-10-31 | Yeda Res & Dev | Modified avidin and streptavidin molecules and use thereof |
| FI100276B (fi) * | 1996-02-06 | 1997-10-31 | Orion Yhtymae Oy | Menetelmä analyyttien ei-kilpailevaa määritystä varten |
| DE19724787A1 (de) * | 1997-06-06 | 1998-12-10 | Biotez Berlin Buch Gmbh Bioche | Streptavidin/Avidin beschichtete Oberflächen |
| EP0922958B1 (fr) * | 1997-12-11 | 2002-10-02 | Roche Diagnostics GmbH | Réduction d'interférence dans les méthodes diagnostiques utilisants les peptides comportant les D-acides amines |
| US6410692B2 (en) * | 1998-02-02 | 2002-06-25 | Novadx, Inc. | Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix |
| ATE221657T1 (de) * | 1998-05-06 | 2002-08-15 | Roche Diagnostics Gmbh | Entstörung durch rheumafaktoren |
| ATE253126T1 (de) * | 1998-08-25 | 2003-11-15 | Univ Washington | Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen |
| US6143507A (en) * | 1998-10-29 | 2000-11-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | High throughput compatible assay for receptor-TRAF interactions |
| US6629040B1 (en) | 1999-03-19 | 2003-09-30 | University Of Washington | Isotope distribution encoded tags for protein identification |
| EP1295123A4 (fr) | 2000-06-12 | 2005-02-02 | Univ Washington | Marquage et isolation selectifs de phosphopeptides et applications a l'analyse proteomique |
| US7223534B2 (en) * | 2002-05-03 | 2007-05-29 | Kimberly-Clark Worldwide, Inc. | Diffraction-based diagnostic devices |
| US7214530B2 (en) * | 2002-05-03 | 2007-05-08 | Kimberly-Clark Worldwide, Inc. | Biomolecule diagnostic devices and method for producing biomolecule diagnostic devices |
| US7771922B2 (en) * | 2002-05-03 | 2010-08-10 | Kimberly-Clark Worldwide, Inc. | Biomolecule diagnostic device |
| US7223368B2 (en) * | 2002-05-03 | 2007-05-29 | Kimberly-Clark Worldwide, Inc. | Diffraction-based diagnostic devices |
| US7118855B2 (en) * | 2002-05-03 | 2006-10-10 | Kimberly-Clark Worldwide, Inc. | Diffraction-based diagnostic devices |
| US7485453B2 (en) * | 2002-05-03 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Diffraction-based diagnostic devices |
| US7091049B2 (en) * | 2002-06-26 | 2006-08-15 | Kimberly-Clark Worldwide, Inc. | Enhanced diffraction-based biosensor devices |
| US7169550B2 (en) * | 2002-09-26 | 2007-01-30 | Kimberly-Clark Worldwide, Inc. | Diffraction-based diagnostic devices |
| US20050112586A1 (en) * | 2003-11-24 | 2005-05-26 | Roland Janzen | Method and composition for stabilizing liquid reagents |
| US20060114172A1 (en) * | 2004-11-26 | 2006-06-01 | Giotti, Inc. | Method and apparatus for LED based modular display |
| US8445293B2 (en) * | 2005-02-09 | 2013-05-21 | Rapid Pathogen Screening, Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
| US8669052B2 (en) * | 2008-06-10 | 2014-03-11 | Rapid Pathogen Screening, Inc. | Lateral flow nucleic acid detector |
| US9068981B2 (en) | 2009-12-04 | 2015-06-30 | Rapid Pathogen Screening, Inc. | Lateral flow assays with time delayed components |
| US8962260B2 (en) | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
| US20130196310A1 (en) | 2008-05-20 | 2013-08-01 | Rapid Pathogen Screening, Inc. | Method and Device for Combined Detection of Viral and Bacterial Infections |
| US8609433B2 (en) * | 2009-12-04 | 2013-12-17 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
| US8815609B2 (en) | 2008-05-20 | 2014-08-26 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with diverting zone |
| US20110086359A1 (en) * | 2008-06-10 | 2011-04-14 | Rapid Pathogen Screening, Inc. | Lateral flow assays |
| CN103620407B (zh) * | 2011-06-29 | 2016-09-21 | 美迪恩斯生命科技株式会社 | 非特异性反应抑制剂、非特异性反应抑制方法及试剂盒 |
| JPWO2013018836A1 (ja) * | 2011-08-01 | 2015-03-05 | 日本たばこ産業株式会社 | 生物学的試料中の物質を検出する工程において、非特異的結合を抑制する方法、当該方法に使用するための剤 |
| US10808287B2 (en) | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
| JP7245907B2 (ja) * | 2018-09-25 | 2023-03-24 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 共役分子トラップを使用して、アッセイからビオチン干渉を取り除く方法および組成物 |
| EP3857227B1 (fr) * | 2018-09-25 | 2023-10-25 | Siemens Healthcare Diagnostics Inc. | Composition pour éliminer l'interférence d'haptène dans des essais |
| CN112129933B (zh) * | 2019-06-25 | 2024-01-05 | 迈克生物股份有限公司 | 一种免疫分析系统中抗生物素干扰的试剂、试剂盒及方法 |
| CN112129955B (zh) * | 2019-06-25 | 2023-04-07 | 迈克生物股份有限公司 | 睾酮检测试剂盒 |
| EP4290235A1 (fr) * | 2022-06-10 | 2023-12-13 | Siemens Healthcare Diagnostics Products GmbH | Procédé de neutralisation d'une interférence de la biotine lors des essais de liaison |
| CN116773793A (zh) * | 2023-03-16 | 2023-09-19 | 中元汇吉生物技术股份有限公司 | 一种链霉亲和素阻断剂和检测试剂盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8314523D0 (en) * | 1983-05-25 | 1983-06-29 | Lowe C R | Diagnostic device |
| EP0155854B1 (fr) * | 1984-03-22 | 1990-09-26 | Bresatec Limited | Matériel de test biologique non-radioactif |
| JP2624470B2 (ja) * | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
| US4839293A (en) * | 1986-02-24 | 1989-06-13 | The Trustees Of Columbia University In The City Of New York | DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
| DE3800644A1 (de) * | 1988-01-12 | 1989-07-20 | Boehringer Mannheim Gmbh | Verfahren zum hochspezifischen nachweis von nukleinsaeuren in loesung |
| US5268306A (en) * | 1988-02-29 | 1993-12-07 | Boehringer Mannheim Gmbh | Preparation of a solid phase matrix containing a bound specific binding pair |
| US4914040A (en) * | 1988-03-03 | 1990-04-03 | Boehringer Mannheim Gmbh | Reagent and method for determination of a polyvalent substance using an immunoaggregate |
| DE3915135A1 (de) * | 1989-05-09 | 1990-11-15 | Boehringer Mannheim Gmbh | Verfahren zum nachweis spezifisch bindefaehiger substanzen in koerperfluessigkeiten |
| US5252466A (en) * | 1989-05-19 | 1993-10-12 | Biotechnology Research And Development Corporation | Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them |
| US5252743A (en) * | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| DE4040669A1 (de) * | 1990-12-19 | 1992-06-25 | Behringwerke Ag | Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik |
| EP0544005A4 (en) * | 1991-06-17 | 1993-12-15 | Seiko Epson Corporation | Heat developing apparatus |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| DE4135543A1 (de) * | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | Rekombinantes core-streptavidin |
| US5260004A (en) * | 1991-12-02 | 1993-11-09 | The United States Of America As Represented By The Secretary Of The Army | Process of making Langmuir-Blodgett films having photo-electronic properties |
| US5487975A (en) * | 1993-11-15 | 1996-01-30 | Ventana Medical Systems, Inc. | Biotin/avidin formulation |
-
1995
- 1995-03-03 JP JP7522705A patent/JP3027770B2/ja not_active Expired - Lifetime
- 1995-03-03 CA CA002184386A patent/CA2184386C/fr not_active Expired - Lifetime
- 1995-03-03 US US08/700,435 patent/US5863740A/en not_active Expired - Lifetime
- 1995-03-03 WO PCT/EP1995/000776 patent/WO1995023801A1/fr active IP Right Grant
-
1996
- 1996-09-04 FI FI963461A patent/FI114341B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5863740A (en) | 1999-01-26 |
| WO1995023801A1 (fr) | 1995-09-08 |
| JP3027770B2 (ja) | 2000-04-04 |
| CA2184386A1 (fr) | 1995-09-08 |
| FI963461A0 (fi) | 1996-09-04 |
| JPH09510289A (ja) | 1997-10-14 |
| CA2184386C (fr) | 2005-10-18 |
| FI963461A (fi) | 1996-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114341B (fi) | Avidiinin tai streptavidiinin käyttö häiriönpoistoaineena immunologisissa määrityksissä ja määritysmenetelmät, joissa käytetään tätä ainetta | |
| JP3556228B2 (ja) | 複数の抗原を使用した特異的免疫グロブリンの測定 | |
| KR100252688B1 (ko) | 면역검정법에사용하기위한간섭억제제 | |
| JP3363166B2 (ja) | 相互に対する極めて高い特異的親和性を有するペプチド対をイン・ビトロ診断分野に使用する方法 | |
| EP0648334A4 (fr) | Dosages immunologiques au moyen de conjugues enzymatiques colores complexes. | |
| JP5675782B2 (ja) | 標識化プローブ−水溶性担体複合体 | |
| AU748402B2 (en) | Method for isolating a target biological material, capture phase, detecting phase and reagent containing them | |
| US20060057647A1 (en) | Detection and identification of saxiphilins using saxitoxin-biotin conjugates | |
| WO2019020599A1 (fr) | Protéine de fusion à épitopes multiples d'un antigène du vhc et ses utilisations | |
| JPH02253162A (ja) | 特異的結合能を有する物質と結合したエクオリンを用いる検出法 | |
| US5674677A (en) | Immunoassay technique using histidine tags, metals, and chelating agents | |
| US5840834A (en) | Technique for joining amino acid sequences and novel composition useful in immunoassays | |
| EP0228225A2 (fr) | Trousse pour les essais immunologiques et procédé utilisant une surface solide modifiée | |
| JPH03255959A (ja) | ポリマー | |
| JP2001511820A (ja) | サイクロスポリン誘導体およびその使用 | |
| KR20110130384A (ko) | 효소가 집적된 미세튜브를 이용한 정량분석법 | |
| JP5559465B2 (ja) | アビジン類結合担体、その製造方法及びその使用方法 | |
| WO2007124593A1 (fr) | Amplification ramifiées de peptides et leurs utilisations | |
| JP4437003B2 (ja) | Ｅｖｈ１ドメインまたはｅｖｈ１ドメインを有するタンパク質とｅｖｈ１結合ドメインまたはｅｖｈ１結合ドメインを有するタンパク質との相互作用を調節する化合物をスクリーニングする方法およびその相互作用を検出する方法 | |
| JP3923076B2 (ja) | 特定位にとり込まれたマーカー基およびハプテンを有するオリゴマー担体分子 | |
| JP2001305137A (ja) | 特異的複合体の固定化方法および測定方法 | |
| Rao | Controlled immobilization of biotinylated horseradish peroxidase in the development of novel biosensors and bioreactors | |
| JPH11508036A (ja) | 抗−ｈｉｖ−１または抗−ｈｉｖ−２抗体を検出するための改良されたハプテン−ペプチド結合物 | |
| Ngo et al. | Enzyme Immunoassays Using Tagged Enzyme-Ligand Conjugates | |
| JPH0466870A (ja) | 新規な標識体及びそれを用いた免疫測定法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Name/ company changed in application |
Owner name: ROCHE DIAGNOSTICS INC. |
|
| FG | Patent granted |
Ref document number: 114341 Country of ref document: FI |
|
| MA | Patent expired |